SPG601, an oral treatment for fragile X syndrome that's now in clinical testing, has been granted orphan drug status in the European Union.| Fragile X News Today
Kaerus is planning a proof-of-concept Phase 2 trial for KER-0193 after its fragile X syndrome treatment was found safe in healthy adults.| Fragile X News Today
A single dose of Spinogenix’s investigational oral therapy SPG601 led to significant reductions in a measure of abnormal brain activity among men with fragile X syndrome, according to top-line results from a Phase 2a trial. Announced by Spinogenix in a company press release, the results from the placebo-controlled Phase 2a trial (NCT06413537) were also presented […] The post SPG601 found to reduce measure of abnormal brain activity in fragile X appeared first on Fragile X News Today.| Fragile X News Today – The Web's Daily Resource for Fragile X News
The clinical trial is assessing the safety of Allyx Therapeutics' ALX-001 versus a placebo when given to adults twice daily for 28 days.| Parkinson's News Today
Investigational therapy BPN14770 has been granted orphan drug status by the U.S. Food and Drug Administration for the treatment of fragile X syndrome.| Fragile X News Today